GHRP-6 vs MOTS-c

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

GHRP-6MOTS-c
CategoryPeptidesPeptides
Standard DoseResearch indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.
TimingOn empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical.Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.
Cycle Duration8-16 week cycles.8-16 week cycles.
Evidence Levelmoderate_humanEmerging (strong preclinical)
A

GHRP-6

Peptides

Mechanism

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates GH release through activation of the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) on pituitary somatotrophs. It acts via dual sites — pituitary and hypothalamic — possibly involving regulatory factors beyond GHRH and somatostatin. GHRP-6 also stimulates ghrelin-mediated appetite signaling, increases cortisol and prolactin release, and has demonstrated cytoprotective properties including cardioprotection.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

On empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical.

Cycle Duration

8-16 week cycles.

Side Effects

  • Intense hunger (primary distinguishing side effect)
  • Water retention
  • Cortisol elevation
  • Prolactin elevation
  • Tingling and numbness
  • Injection site pain

Contraindications

  • Active cancer
  • Obesity (significant appetite stimulation)
  • Cushing's syndrome
  • Pregnancy and breastfeeding

Best Stacking Partners

CJC-1295 (no DAC)Sermorelin
B

MOTS-c

Peptides

Mechanism

MOTS-c is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA gene of the mitochondrial genome. It primarily acts through the folate-AICAR-AMPK pathway: by regulating the folate cycle and de novo purine biosynthesis, it increases AICAR accumulation, which phosphorylates and activates AMPK. This enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and mimics exercise-mediated physiological responses. Skeletal muscle MOTS-c levels increase 11.9-fold in response to acute exercise in young men.

Standard Dosing

Research indicates 5-10 mg administered 3-5 times per week via subcutaneous injection.

Timing

Morning administration preferred. Can be dosed pre-workout for enhanced exercise performance.

Cycle Duration

8-16 week cycles.

Side Effects

  • Injection site reactions
  • Mild fatigue post-injection
  • Transient flushing
  • Muscle soreness (exercise-mimetic effect)

Contraindications

  • Pregnancy and breastfeeding
  • Type 1 diabetes (insulin sensitivity changes require monitoring)
  • Not FDA-approved
  • Limited human safety data
  • Active cancer (metabolic pathway activation)

Best Stacking Partners

5-Amino-1MQAOD-9604Semaglutide

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →